Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd, an Australian-based trailblazer in the development of Synthetic Anti-infectives, has successfully concluded its data analysis for the Phase I/II clinical trial of RECCE® 327 (R327) as a treatment for burn wound infections. Their significant findings revealed that RECCE® 327 adeptly treated bacterial infections in the patients observed. Notably, the bacterial pathogens addressed by R327 include those identified by the World Health Organisation as major threats to global health.

In the initial stages of the R327 treatment, clinicians documented a notable reduction in bacterial infections, often within the first 24 hours. This broad-spectrum antibiotic has shown efficacy against both Gram-positive and Gram-negative pathogens. These pathogens are specifically mentioned in the WHO’s Priority Pathogen list of antibiotic-resistant bacteria, highlighting the gravity of R327’s achievement in this realm. The bacteria in question are notoriously known for being multidrug-resistant and challenging to treat.

Endpoints in the clinical trial focused on clinical wound assessments and microbial cultures of wound swabs. Such assessments assist in grading specific parameters, including erythema and swelling, which are vital in gauging the severity of a diabetic foot wound infection. The severity subsequently aids medical professionals in determining the nature and urgency of both antibiotic and surgical interventions.

Safety and tolerability were of paramount importance in the trials. Patients treated with R327 have shown positive indications in these areas. There were, however, observations that any missed doses led to potential wound deterioration. This observation is consistent with other interrupted wound treatments. Among those who did not complete dosing, one patient needed systemic antibiotics due to unrelated co-morbidities, which led to their exclusion from the study. Another patient, post-surgery, did not respond positively to the cold application of R327 on their wound. Yet, it’s reassuring to note that no severe adverse events have been reported among participants.

Support from the West Australian Government has not only been pivotal for this study but has also unlocked other exciting opportunities for Recce Pharmaceuticals. These include the initiation of a Phase I/II Diabetic Foot Infection trial, the use of RECCE® 327G as a topical agent under specific schemes, and considerable interest from military organizations for the use of R327 and R327G.

However, challenges have arisen in recruitment for Stage 1 of the clinical trial. Fiona Stanley Hospital Burns Unit experienced challenges recruiting suitable patients, largely attributed to COVID protocols which introduced preventative antibiotic infection control practices. This had a cascading effect, leading to potential candidates not meeting the specific protocol requirements, thereby impacting the overall recruitment process.

Adapting to these challenges, clinical investigators are preparing a fresh protocol for the next phase. The upcoming Stage 2 Clinical trial will adopt a ‘head-to-head’ approach, where R327G treatment is pitted against existing treatment standards of care for patients with infected burn wounds.

James Graham, the Chief Executive Officer of Recce Pharmaceuticals Ltd, expressed gratitude to the West Australian Government for their support. He emphasized the promising potential of this new class of anti-infective in combating deadly bacterial pathogens. Graham eagerly anticipates the launch of Stage 2, viewing the previous study as a foundational step.

Recce Pharmaceuticals Ltd is in the vanguard of crafting a new class of Synthetic Anti-Infectives. Their vision seeks to combat the pressing global health issues stemming from antibiotic-resistant superbugs and emerging viral threats. The FDA’s recognition of RECCE® 327, granting it the Qualified Infectious Disease Product designation and labeling it for Fast Track Designation, serves as a testament to its potential impact. The journey, however, is ongoing, with further clinical testing required to comprehensively assess RECCE® 327’s safety and efficacy.

Read full article here: https://stockhound.com.au/recce-pharmaceuticals-triumphs-with-recce-327-in-burn-wound-infections-clinical-trial-asxrce/

Recce Pharmaceuticals Triumphs with RECCE® 327 in Burn Wound Infections Clinical Trial (ASX:RCE)